Retraction to: Journal of Hematology & Oncology (2022) 15:112 https://doi.org/10.1186/s13045-022-01338-9
The Editor-in-Chief has retracted this article because of significant concerns regarding a number of Figures presented in this work, which question the integrity of the data. The Editor-in-Chief therefore no longer has confidence in the integrity of the data in this article.
Lingxi Jiang does not agree to this retraction. Zengyu Feng, Kexian Li, Kai Qin, Juyong Liang, Minmin Shi, Yang Ma, Shiwei Zhao, Huaiyu Liang, Dongni Han, Baiyong Shen, Chenghong Peng and Hao Chen have not responded to any correspondence from the editor about this retraction.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Feng, Z., Li, K., Qin, K. et al. Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. J Hematol Oncol 16, 109 (2023). https://doi.org/10.1186/s13045-023-01506-5
Published:
DOI: https://doi.org/10.1186/s13045-023-01506-5